These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 2464961)
61. Prospects for the prevention and therapy of infections with the human immunodeficiency virus. Vogt M; Hirsch MS Rev Infect Dis; 1986; 8(6):991-1000. PubMed ID: 3541131 [TBL] [Abstract][Full Text] [Related]
62. [Repertoire of epitopes of human immunodeficiency virus proteins and the search for vaccines and diagnostic kits]. Kharchenko EP; Klimenko AP Dokl Akad Nauk SSSR; 1992; 322(1):189-92. PubMed ID: 1380907 [No Abstract] [Full Text] [Related]
63. Toward an understanding of the correlates of protective immunity to HIV infection. Haynes BF; Pantaleo G; Fauci AS Science; 1996 Jan; 271(5247):324-8. PubMed ID: 8553066 [TBL] [Abstract][Full Text] [Related]
64. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M J Virol; 2017 May; 91(9):. PubMed ID: 28179536 [TBL] [Abstract][Full Text] [Related]
65. NIH conference. HIV vaccine development: a progress report. Hoth DF; Bolognesi DP; Corey L; Vermund SH Ann Intern Med; 1994 Oct; 121(8):603-11. PubMed ID: 8085693 [TBL] [Abstract][Full Text] [Related]
66. Immunization programs and human immunodeficiency virus. La Montagne JR Rev Infect Dis; 1989; 11 Suppl 3():S639-43. PubMed ID: 2762702 [TBL] [Abstract][Full Text] [Related]
67. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. Gupta P; Balachandran R; Ho M; Enrico A; Rinaldo C J Virol; 1989 May; 63(5):2361-5. PubMed ID: 2704079 [TBL] [Abstract][Full Text] [Related]
68. Toward an AIDS vaccine. Walker BD; Burton DR Science; 2008 May; 320(5877):760-4. PubMed ID: 18467582 [TBL] [Abstract][Full Text] [Related]
69. Immunology of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. An update. Seligmann M; Pinching AJ; Rosen FS; Fahey JL; Khaitov RM; Klatzmann D; Koenig S; Luo N; Ngu J; Riethmüller G Ann Intern Med; 1987 Aug; 107(2):234-42. PubMed ID: 3300461 [TBL] [Abstract][Full Text] [Related]
70. NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Fauci AS; Schnittman SM; Poli G; Koenig S; Pantaleo G Ann Intern Med; 1991 Apr; 114(8):678-93. PubMed ID: 1672248 [TBL] [Abstract][Full Text] [Related]
71. Immunology of infection with the human immunodeficiency virus (HIV). A view from the III International Conference on AIDS. Koenig S; Rosenberg ZF Ann Intern Med; 1987 Sep; 107(3):409-11. PubMed ID: 3304052 [No Abstract] [Full Text] [Related]
72. Vaccine development for HIV infection. Bolognesi D J Am Acad Dermatol; 1990 Jun; 22(6 Pt 2):1295-9. PubMed ID: 2362019 [TBL] [Abstract][Full Text] [Related]
74. Cellular immunity and a type 1 cytokine profile in protection against HIV infection and progression to AIDS. Clerici M; Shearer GM Res Immunol; 1994; 145(8-9):635-41; discussion 641-3. PubMed ID: 7754213 [No Abstract] [Full Text] [Related]
75. AIDS vaccine: present problems and future perspectives. Ennen J; Norley SG; Kurth R Int J Clin Lab Res; 1992; 22(4):206-10. PubMed ID: 1467536 [TBL] [Abstract][Full Text] [Related]
76. Perspectives of HIV vaccine developments. Ferdinand FJ; Dorner F; Kurth R J Virol Methods; 1987 Aug; 17(1-2):63-7. PubMed ID: 3312268 [TBL] [Abstract][Full Text] [Related]
77. Towards anti-HIV vaccines. Tyrrell DA Vaccine; 1988 Jun; 6(3):211-2. PubMed ID: 3420971 [TBL] [Abstract][Full Text] [Related]
78. Challenges of HIV vaccine development. Stablein DM Stat Med; 1990 Dec; 9(12):1425-31; discussion 1433-7. PubMed ID: 2281230 [No Abstract] [Full Text] [Related]
79. Getting to market: the scientific and legal climate for developing an AIDS vaccine. Mariner WK; Gallo RC Law Med Health Care; 1987; 15(1-2):17-26. PubMed ID: 3669712 [No Abstract] [Full Text] [Related]
80. HIV-specific cytotoxic T lymphocytes. Plata F Res Immunol; 1989 Jan; 140(1):89-91. PubMed ID: 2657912 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]